Want to create an interactive transcript for this episode?
Podcast: OncLive® On Air
Episode: Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD
Description: In today’s episode, supported by Ascentage Pharma, we had the pleasure of speaking with Elias Jabbour, MD, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
In our exclusive interview, Dr Jabbour discussed the 1.5-year follow-up data from a phase 1b trial (NCT04260022) investigating olverembatinib (HQP1351) in patients with heavily pretreated chronic-phase chronic myeloid leukemia (CML), enrollment considerations for the registrational phase 3 POLARIS-2 trial (NCT06423911) that is further evaluating the agent in this population, and potential future research directions in CML.